Android app on Google Play

Orexigen (OREX) to Update on Contrave Progress During Dec. 18th Event

December 4, 2012 8:09 AM EST Send to a Friend
Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that the Company will provide details of obesity therapeutics market research including the results of surveys of 1,000 physicians and 6,000 patients during an Analyst Day event on December 18, 2012. The Company will also provide an update to the Contrave® Light Study and discuss U.S. and EU regulatory planning.

The Analyst Day event will be held in New York City on December 18, 2012 from 9 a.m. to 12 p.m. Eastern Time.

While attendance in person is by invitation only, Orexigen will webcast the Analyst Day presentations. The webcast can be accessed live on the Investor Relations section of the Orexigen website at www.orexigen.com and will be archived for 14 days following the call.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment